1. Generics Bulletin
  2. >>Legal & IP

AbbVie Humira Lawsuit Withstands Alvotech Attack

Attempt Fails To Dismiss Adalimumab Litigation Ahead Of FDA Decision On AVT02 Biosimilar

 
• By Dave Wallace

Alvotech has failed in an attempt to dismiss US litigation initiated by AbbVie over Alvotech’s AVT02 proposed rival to higher-strength Humira. The company is expecting an FDA decision on the adalimumab biosimilar this month.

Blue Button Dismiss
Alvotech had attempted to have the litigation dismissed • Source: Alamy

Alvotech’s attempt to have a US court dismiss patent litigation initiated by AbbVie over Humira (adalimumab) has fallen on deaf ears, with an Illinois district court rejecting the biosimilars firm’s arguments that the originator had sued the wrong Alvotech entity and that the venue was improper.

The decision comes as Alvotech is anticipating US Food and Drug Administration action on its AVT02 proposed higher-strength

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.